The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

In recent trading, OS Therapies Inc (OSTX) stock price has shown some volatility, fluctuating -11.02% over the last five trades and -2.24% over the past 30 trades. This represents a notable shift from ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

HER2, showing improved event-free and overall survival in lung metastatic osteosarcoma. The start-up, which joined JLABS and ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following ...

The laboratory of the latest Nobel Prize winner in Chemistry David Baker, headed by researcher Susana Vázquez, talks about ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...